| Name | Title | Contact Details |
|---|---|---|
Peter Blaisdell |
Chief Revenue Officer | Profile |
Nathan Stewart |
Vice President of Product Design and Content | Profile |
Becky Banasik |
SVP Client Success | Profile |
Sarah Fink |
AVP, Product Marketing | Profile |
Zachary Fleming |
VP of Product | Profile |
Ellipse Technologies is a privately held medical device company that is dedicated to the design, development and successful commercialization of non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. As part of its product portfolio, the company has developed remote controlled distraction systems using magnets which may eliminate the need for additional surgeries for adjustment. The initial revolutionary products restore proper anatomic position and alignment of the spine and correct limb length discrepancies of the femur and tibia. Ellipse is located in Irvine, California.
Southern Veterinary Partners is a network of animal hospitals in the South that provides high quality veterinary care to companion animals with exceptional client experiences.
AFB International is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Saint Charles, MO. To find more information about AFB International, please visit www.afbinternational.com
Lawndale Christian Health Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."